-
I-BET151: Epigenetic Assay Design Beyond Cancer
2026-09-01
I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for dissecting transcriptional control in cancer biology and organoid models. This article uses a PDX1-mutant macaque study to develop a rigorous, multi-layer assay strategy that separates chromatin perturbation from developmental and m6A-associated phenotypes.
-
Shufeng Xingbi Therapy in Allergic Rhinitis Rats
2026-09-01
This preprint investigates how Shufeng Xingbi Therapy affects allergic rhinitis in rats by integrating nasal inflammation, Th1/Th2-associated signaling, gut microbiota, and short-chain fatty acids. Its main contribution is a microbiota–immune interpretation of treatment response, while the findings remain preliminary because the work is an animal preprint without direct causal validation.
-
Sulfamonomethoxine Biotransformation in Granular Sludge
2026-08-31
The reference study shows that biodegradation, rather than adsorption alone, is the dominant removal process for sulfamonomethoxine in aerobic granular sludge. Its mechanistic contribution is the identification of hydroxylamine and hydroxylamine oxidoreductase as important drivers of SMM transformation, alongside evidence for a previously unrecognized TP202 pathway.
-
CUDC-907: Practical In Vitro Protocol Guide
2026-08-31
CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis. It should be used as a research reagent in validated laboratory assays, not for diagnostic, therapeutic, or clinical applications.
-
Sitagliptin Phosphate Monohydrate in Cell Assays
2026-08-30
This scenario-driven guide explains how Sitagliptin phosphate monohydrate, SKU A4036, can support DPP-4, viability, proliferation, and cytotoxicity workflows. It covers assay interpretation, solvent compatibility, protocol optimization, metabolic controls, and practical supplier-selection criteria.
-
Z-WEHD-FMK: Reading Caspase-1 in Pyroptosis
2026-08-29
Z-WEHD-FMK is an irreversible, cell-permeable inhibitor for dissecting inflammatory caspase activity. This guide connects inhibitor timing and orthogonal readouts with new mechanistic insight into HOXC8-regulated pyroptosis and pathogen-associated Golgi remodeling.
-
Fingolimod (FTY720): Mechanism and Research Use
2026-08-28
Fingolimod, also called FTY720, is an oral S1P-receptor modulator and immunomodulatory agent for MS. Its best-established action is lymphocyte egress inhibition, while BDNF and ERK1/2 findings support a preclinical neurobiology research application rather than a proven clinical neuroprotection claim.
-
Sex Differences in Angiotensin II Hypertension
2026-08-28
The reference study used radiotelemetry in conscious, freely moving mice to show that chronic angiotensin II produces substantially greater hypertension in males than females. Gonadectomy, baroreflex testing, and ganglionic blockade further implicated sex hormones, autonomic control, and baroreflex resetting in the divergent blood-pressure responses.
-
Psora 4: Practical Kv1.3 Blocker Workflows
2026-08-27
Psora 4 is a selective Kv1.3 blocker for connecting ion-channel activity with calcium signaling, effector memory T-cell responses, and inflammatory disease models. This workflow-focused guide covers dosing, assay integration, KCNE4-aware interpretation, solubility control, and troubleshooting.
-
TRPV1+ Nerves and the Somato-Autonomic Reflex
2026-08-27
Song et al. identify a neural circuit in which targeted stimulation of TRPV1+ peripheral afferents suppresses systemic inflammation through coordinated brainstem, endocrine, vagal, sympathetic, and splenic responses. The study provides a mechanistic framework for interpreting somatic stimulation as a regulator of immune signaling, while also defining important limits for translation beyond preclinical models.
-
Carvacrol: Reliable Cell Assay Workflows
2026-08-26
Carvacrol (SKU C6244) offers a practical, mechanism-aware option for cell viability, cell cycle, apoptosis, and redox-channel experiments. This guide explains formulation, controls, storage, interpretation, and vendor-selection criteria that improve reproducibility without overstating what current evidence demonstrates.
-
Doxycycline: Designing Decision-Ready Cancer Assays
2026-08-26
Doxycycline is more than a tetracycline antibiotic: it is a mechanistically layered antimicrobial agent for research and metalloproteinase inhibitor. This guide shows how to design cancer research assays that distinguish antimicrobial, protease-related, antiproliferative, and delivery-dependent effects.
-
CB-839: Translating Splicing-Linked Metabolic Stress
2026-08-25
PRMT5-linked splicing defects can expose glutamine metabolic dependencies in MYCN-amplified neuroblastoma. This article outlines how CB-839 (Telaglenastat), a selective reversible GLS1 inhibitor, can help translational researchers test that vulnerability while separating upstream spliceosomal biology from direct glutaminolysis inhibition.
-
Vasopressin Analogues: From Hormone to Multitasking Peptides
2026-08-25
The reference review explains how vasopressin biology, receptor selectivity, and peptide engineering have produced analogues with distinct antidiuretic, vasoconstrictive, and therapeutic profiles. Its central contribution is a structure–function framework linking natural peptides such as lypressin with engineered candidates such as desmopressin and terlipressin, while identifying emerging but still preliminary antiviral applications.
-
NF 449 Workflows for P2X1 Platelet Studies
2026-08-24
NF 449 enables high-resolution separation of P2X1-dependent platelet signaling from broader purinergic responses. This practical guide covers receptor assays, platelet aggregation, collagen challenge experiments, selectivity controls, and troubleshooting for antithrombotic agent research.